Comparative Genomic Authentication of Unani Medicinal Resins and Their Botanical Sources

Abstract

Unani medicinal resins are complex natural products used in formulations intended for anti-inflammatory, antimicrobial, gastrointestinal, respiratory, and wound-related indications. Their therapeutic identity and safety depend on accurate botanical authentication, yet conventional macroscopic, microscopic, and chemical methods may be limited by processing, environmental variation, substitution, adulteration, and the presence of closely related taxa. Comparative genomic authentication, including DNA barcoding, metabarcoding, whole-plastid sequencing, and genome-informed chemotaxonomy, provides a complementary approach for establishing the botanical sources of resinous drugs. This review examines the scientific rationale, clinical relevance, diagnostic workflow, limitations, and emerging applications of genomic authentication in Unani pharmacognosy. The approach is particularly valuable for distinguishing source species, detecting undeclared plant material, supporting batch-level quality control, and linking genetic identity with chemical and biological activity. However, genomic data should not be interpreted in isolation because resins often contain degraded DNA, mixed biological material, endophytic organisms, and exogenous contaminants. Integrated testing that combines validated molecular markers with microscopy, chromatographic fingerprinting, pharmacopeial standards, and authenticated reference materials is therefore essential. Harmonized guidelines, curated reference databases, and transparent reporting standards will be required before comparative genomic authentication can become routine in clinical supply chains.

Introduction

Unani medicine uses numerous resinous substances obtained from trees, shrubs, and herbaceous plants. These materials may be collected as exudates, oleo-gum-resins, balsams, latexes, or hardened secretions and are incorporated into single drugs and compound preparations. Their names may refer to traditional pharmacopoeial identities rather than a single universally accepted botanical species, creating challenges in international trade and clinical standardization. Accurate authentication is therefore a medical and regulatory concern, not merely a taxonomic exercise. Incorrectly identified or substituted resins may have reduced efficacy, altered pharmacological activity, or unexpected toxicological properties.

Comparative genomic authentication uses sequence information to compare an unknown sample with genetically verified botanical references. Common targets include chloroplast loci such as rbcL, matK, psbA-trnH, and trnL, as well as nuclear regions such as internal transcribed spacer sequences. Because no single marker performs equally well across all resin-producing taxa, a multilocus strategy is often preferable. Molecular results can be strengthened by comparing the genetic profile with organoleptic characteristics, microscopic structures, chemical constituents, and documented geographical provenance.

Epidemiology / Disease Burden

The burden associated with misidentified medicinal resins is distributed across patients, practitioners, manufacturers, and public health systems. Unani medicines are used by large populations in South Asia and are increasingly available through global complementary medicine markets. Resinous drugs frequently move through complex collection and trading networks in which vernacular names, regional synonyms, and variable processing practices may obscure botanical origin. Deforestation, overharvesting, climate-related stress, and commercial demand further increase the probability of substitution and intentional adulteration.

Although the true incidence of adverse events attributable specifically to resin misidentification is difficult to quantify, quality investigations have repeatedly shown discrepancies between labeled and molecularly identified plant materials in herbal products. The clinical consequences may include therapeutic failure, allergic reactions, gastrointestinal irritation, renal or hepatic toxicity, contamination with undeclared pharmacologically active substances, and exposure to heavy metals or microorganisms introduced during collection and storage. At a population level, poor authentication also undermines confidence in traditional medicine and complicates pharmacovigilance because the actual botanical exposure may be unknown.

Pathophysiology

Resins exert biological effects through chemically diverse constituents, including terpenoids, phenolic compounds, volatile fractions, polysaccharides, and oxidized derivatives. Their pharmacological activity can involve modulation of cyclooxygenase and lipoxygenase pathways, nuclear factor kappa B signaling, oxidative stress responses, microbial membrane integrity, and cytokine production. These effects are species-dependent and may vary with age, tissue source, climate, soil, season, extraction method, and storage.

Botanical substitution can therefore change the molecular composition responsible for therapeutic or adverse effects. A resin from a related species may appear visually similar while containing different diterpenes, sesquiterpenes, allergenic proteins, or toxic secondary metabolites. Genomic authentication addresses the upstream cause of this variation by confirming biological identity before pharmacological interpretation. It does not, however, measure concentration, degradation, or bioavailability of active compounds. DNA establishes source identity, whereas chemical and biological assays are needed to characterize the functional phenotype of the final product.

Risk Factors

Important risk factors include ambiguous vernacular nomenclature, reliance on untrained collectors, harvesting outside the recommended botanical range, substitution with cheaper materials, and the sale of powdered or extensively processed products. Heating, drying, solvent extraction, fermentation, and prolonged storage may fragment or remove DNA, reducing molecular assay sensitivity. Resins can also contain pollen, bark fragments, fungal DNA, insect material, soil particles, or DNA from multiple plant species, producing mixed sequencing profiles.

Additional risks arise from incomplete reference databases and misidentified voucher specimens. A sequence comparison is only as reliable as the reference used for comparison; an incorrectly labeled reference can generate a confident but false assignment. Geographic structure within a species, hybridization, polyploidy, and limited marker resolution may also prevent discrimination between closely related taxa. These factors make laboratory validation, chain-of-custody documentation, negative controls, replicate testing, and expert interpretation essential.

Clinical Features

Clinical manifestations of exposure to an incorrectly authenticated resin are nonspecific and may resemble the underlying disease being treated. Patients may develop lack of expected symptom improvement, abdominal discomfort, nausea, diarrhea, headache, dizziness, urticaria, bronchospasm, or mucosal irritation. Hepatocellular or cholestatic injury, renal dysfunction, and drug-induced hypersensitivity are less common but clinically important possibilities when adulterants or chemically distinct substitute species are present.

Healthcare professionals should consider product-related toxicity when symptoms begin after initiation of a traditional preparation, especially when the preparation is obtained from an unregulated source or when several products are used simultaneously. A careful medication history should record the traditional name, formulation, batch information, dose, duration, source, and co-administered conventional medicines. Genomic authentication does not replace clinical assessment, but it can clarify the exposure and support structured investigation of suspected adverse reactions.

Diagnosis

Authentication begins with representative sampling and documentation of the product's chain of custody. Macroscopic and microscopic examination may identify diagnostic tissues, resin ducts, fibers, crystals, or surface contaminants. Chemical profiling by thin-layer chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry, or liquid chromatography-mass spectrometry can establish characteristic fingerprints and detect unexpected compounds. These methods should be interpreted alongside genomic findings rather than treated as competing approaches.

For genomic analysis, DNA is extracted using protocols adapted to resin-rich, phenolic, or highly oxidized matrices. Polymerase chain reaction amplification may target one or more validated barcode regions. Sanger sequencing is useful for relatively pure samples, whereas next-generation sequencing and metabarcoding are more suitable for mixtures and highly processed materials. Bioinformatic analysis should include quality filtering, contaminant assessment, taxonomic assignment against curated databases, and reporting of read abundance with appropriate caution. A positive identification should require concordance across markers, adequate sequence quality, and compatibility with pharmacopoeial morphology and chemistry.

Whole-plastid genomes and species-specific nuclear markers may provide higher resolution than short universal barcodes. Comparative genomic studies should include authenticated herbarium vouchers, geographically representative collections, technical replicates, and reference materials prepared using realistic processing conditions. Reporting should state the limits of detection, assay specificity, failure rates, database version, and criteria used to call a sample authentic, substituted, mixed, or inconclusive.

Treatment & Management

Management of suspected exposure begins with discontinuing the questionable product when clinically appropriate and assessing the patient for toxicity, allergic reaction, infection, or treatment failure. Laboratory evaluation should be guided by symptoms and may include liver enzymes, bilirubin, renal function, complete blood count, urinalysis, and targeted toxicology. Severe reactions require standard emergency and specialist care. Rechallenge should generally be avoided when a serious hypersensitivity or organ injury is suspected.

At the manufacturing level, risk reduction requires qualified botanical suppliers, authenticated voucher specimens, controlled harvesting, segregated storage, validated identity testing, and batch release criteria. Genomic authentication is most useful as part of a layered quality system that includes chemical standardization, microbial testing, heavy-metal analysis, pesticide assessment, and stability testing. Manufacturers should avoid interpreting a successful DNA result as proof of therapeutic efficacy, because identity alone does not establish dose equivalence or clinical effectiveness.

Recent Advances / Emerging Therapies

Recent advances include portable sequencing platforms, multiplex polymerase chain reaction assays, digital polymerase chain reaction, and long-read sequencing capable of resolving complex genomic regions. Metabarcoding can identify multiple plant constituents in polyherbal products and may reveal undeclared species that are not apparent through microscopy. Genome skimming and complete plastid sequencing are expanding the discriminatory power available for closely related resin-producing plants.

Another important development is the integration of genomic data with metabolomics and pharmacological testing. This combined strategy can identify genotype-associated chemical phenotypes and determine whether a substituted species is likely to have altered efficacy or toxicity. Machine-learning models may assist in classifying samples using multidimensional genetic and chemical data, but such systems require transparent training sets, external validation, and protection against database bias. Emerging therapies are not implied by authentication itself; rather, improved authentication supports safer investigation and more reproducible development of resin-derived medicines.

Guideline Recommendations

Healthcare and regulatory programs should require botanical nomenclature linked to accepted taxonomic authorities, collection locality, plant part, processing method, and voucher documentation. A tiered testing algorithm is appropriate: begin with validated macroscopic and microscopic assessment, add chemical fingerprinting for identity and consistency, and use DNA-based testing when substitution, mixture, processing, or taxonomic ambiguity is suspected. High-risk products, imported batches, and materials with a history of adulteration should receive enhanced molecular surveillance.

Laboratories should use positive and negative controls, replicate analyses, contamination-prevention procedures, validated extraction methods, and curated reference sequences derived from authenticated specimens. Results should be reported as identified, probable, mixed, substituted, or unresolved rather than overstating certainty. Clinicians should document traditional medicines in the medical record, consider possible interactions with anticoagulants, immunosuppressants, antidiabetic drugs, and hepatotoxic medicines, and report suspected adverse events through appropriate pharmacovigilance systems. Professional education should emphasize that genomic authentication complements, rather than replaces, clinical judgment and pharmacopeial quality control.

Conclusion

Comparative genomic authentication offers a powerful method for confirming the botanical sources of Unani medicinal resins and detecting substitution in complex supply chains. Its greatest clinical value lies in improving exposure characterization, reducing preventable quality failures, supporting reproducible pharmacological research, and strengthening confidence in traditional medicines. Because resin matrices may contain degraded DNA and mixed biological material, molecular results require careful validation and integration with morphology, chemistry, toxicology, and documented provenance. Future progress will depend on authenticated genomic reference libraries, internationally harmonized standards, affordable testing platforms, and prospective studies linking verified botanical identity with clinical outcomes. Used within a comprehensive quality framework, genomic authentication can help transform resin-based Unani medicines into more consistently characterized and clinically accountable therapeutic products.